Histamine Desensitization Therapy for Intractable Headaches — CPB 0647 | AETNA Coverage Update

Aetna modified CPB 0647 for histamine desensitization therapy, effective December 9, 2025. Every claim for this treatment against Aetna members is heading for a denial — here's exactly why, and what your billing team needs to do now.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0647 in December 2025. The policy addresses histamine desensitization therapy for intractable headaches — including chronic cluster headaches and migraines. Under this coverage policy, Aetna classifies the treatment as experimental, investigational, or unproven. The primary affected codes are CPT 96365 through 96379, the full range of therapeutic injection and infusion codes your team would use to bill IV histamine infusions or subcutaneous histamine injections.

Quick-Reference Table

Aetna Histamine Desensitization Therapy Coverage Criteria and Medical Necessity Requirements 2025

The short answer: there are no coverage criteria. Aetna's coverage policy under CPB 0647 draws a hard line — histamine desensitization therapy does not meet the bar for medical necessity under any clinical circumstances the payer recognizes.

Aetna's position is that the evidence base is insufficient. Specifically, the payer states that effectiveness has not been established by randomized controlled studies. That is the exact language that triggers an experimental/investigational determination, and it closes the door on medical necessity arguments entirely.

The policy contains no coverage criteria or prior authorization pathway — the therapy is categorically excluded, making a successful PA authorization implausible under the current policy. No letter of medical necessity from a neurologist, no headache diary, no failed-treatment history changes the outcome here. The therapy is categorically excluded, not conditionally covered with prior authorization requirements.

The reimbursement exposure is real. If your neurology or infusion practice has been billing CPT 96365 through 96379 for histamine desensitization therapy without checking this policy, those claims are either already denied or at risk of retrospective recoupment. Pull your Aetna claims for this service line going back 12 months.

Aetna Histamine Desensitization Therapy Exclusions and Non-Covered Indications

CPB 0647 covers one topic, and it covers it with finality. Histamine desensitization therapy is experimental, investigational, or unproven for every indication listed in the policy — no exceptions.

The two primary clinical targets named explicitly are chronic cluster headaches and migraines. Both fall under the ICD-10 ranges G43.001–G43.919 (migraine) and G44.1–G44.9 (cluster headaches and related headache syndromes). The policy also references "other indications," which signals that Aetna is not limiting this exclusion to just these two diagnoses.

The delivery method does not change the outcome either. Both intravenous histamine infusion and subcutaneous histamine injection are named in the policy. Whether your provider bills a single IV push under CPT 96374 or a longer infusion under CPT 96365 and 96366, the result is the same: claim denial.

This is not an unusual stance for Aetna. The pattern here mirrors how the payer has treated other therapies lacking large-scale RCT evidence — think certain complementary approaches in CPB 0388. When Aetna says "effectiveness has not been established by randomized controlled studies," that determination typically holds for years unless new high-quality evidence forces a review.

Coverage Indications at a Glance

Aetna Histamine Desensitization Therapy Billing Guidelines and Action Items 2025

This policy has a December 9, 2025 effective date. If your team has not acted yet, act now. Here are your concrete steps.

1. Pull all Aetna claims for CPT 96365–96379 linked to headache diagnoses.
Run this report back 12 months, not just from December 9, 2025. You want to identify any claims that went through without a denial, because Aetna can recoup on retrospective review. Flag every claim with a primary or secondary diagnosis from G43.001–G43.919, G44.1–G44.9, or R51.0–R51.5 that also billed a therapeutic injection or infusion code in this range.

2. Do not submit prior authorization requests for histamine desensitization therapy.
The policy contains no coverage criteria or prior authorization pathway — the therapy is categorically excluded, making a successful PA authorization implausible under the current policy. Submitting a PA request wastes your team's time and may create a paper trail of attempted billing without a patient-signed ABN. Save your authorization team's bandwidth for services that can actually be authorized.

3. Issue an Advance Beneficiary Notice equivalent before any service.
For Aetna commercial members, use the payer's applicable financial liability notice. Patients need to understand — in writing and before treatment — that this service is not covered and they will be responsible for the full cost. Do this before December 9, 2025 services render, and confirm your consent forms are updated to reflect this specific exclusion.

4. Review your charge capture rules for infusion therapy.
If your EHR or charge capture system auto-populates CPT 96365–96379 for all therapeutic infusion encounters, you need a flag for histamine-specific protocols. Build a hard stop or alert that catches headache diagnosis codes (G43.xxx, G44.xxx, R51.x) combined with a histamine desensitization order. This stops the claim before it generates, not after it denies.

5. Redirect patients to covered headache management options.
Aetna's related policy CPB 0462 governs nonsurgical migraine and cluster headache management. CPB 0113 covers Botulinum Toxin — which is a covered option for chronic migraine under specific criteria. If your neurology team is pursuing histamine desensitization because other treatments have failed, document that treatment history and route the patient toward covered alternatives with a legitimate medical necessity argument. Your billing team should flag these patient files for your medical director or treating neurologist.

6. Talk to your compliance officer if you have active histamine infusion protocols.
If your practice or infusion center has standing orders for histamine desensitization, this policy requires immediate protocol review. Your compliance officer needs to assess the financial liability exposure and whether any corrective action — including voluntary refunds on recent Aetna claims — is warranted. Do not wait on this.

CPT, HCPCS, and ICD-10 Codes for Histamine Desensitization Therapy Under CPB 0647

CPT Codes — Not Covered / Experimental for Histamine Desensitization Therapy

All 15 CPT codes in this range are listed in CPB 0647. Every one of them will generate a claim denial when billed to Aetna for histamine desensitization therapy. They are presented here as reference codes related to the policy — not as covered codes.

Key ICD-10-CM Diagnosis Codes Listed Under CPB 0647

These are the diagnosis codes the policy references, using only the descriptions provided in CPB 0647. Pairing any of these with CPT 96365–96379 for a histamine desensitization encounter will result in a denial under this coverage policy.